Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them

Patent metadata

Field	Value
Publication number	US-10662173-B2
Application number	US-201715676154-A
Country	US
Kind code	B2
Filing date	Aug 14, 2017
Priority date	Jul 23, 2013
Publication date	May 26, 2020
Grant date	May 26, 2020

Abstract

Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.

First claim

The invention claimed is:

1. A method of treating leukemia in a subject in need thereof, comprising administration of a compound of formula (I):

wherein:
W represents a group C-A 3 or a nitrogen atom;
A 1 , A 2 and A 3 each independently of the others, represent a hydrogen or halogen atom, a linear or branched polyhalo-(C 1 -C 6 )alkyl, a linear or branched (C 1 -C 6 )alkyl group or a cycloalkyl,
or A 1 and A 2 , together with the carbon atoms carrying them, form a cycloalkyl or a benzo ring, these two groups being optionally substituted by a halogen atom, a linear or branched (C 1 -C 6 )alkyl group, a linear or branched polyhalo-(C 1 -C 6 )alkyl group, a hydroxy group, a linear or branched (C 1 -C 6 )alkoxy group or —COOH, with the proviso that W represents a group C-A 3 when A 1 and A 2 independently of one another represent a hydrogen or halogen atom, a linear or branched polyhalo-(C 1 -C 6 )alkyl, a linear or branched (C 1 -C 6 )alkyl group or a cycloalkyl;
T represents a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl group optionally substituted by one to three halogen atoms, a group (C 1 -C 4 )alkyl-NR 1 R 2 , or a group (C 1 -C 4 )alkyl-OR 6 ;
R 1 and R 2 independently of one another represent a hydrogen atom or a linear or branched (C 1 -C 6 )alkyl group,
or R 1 and R 2 form with the nitrogen atom carrying them a heterocycloalkyl;
R 3 represents a linear or branched (C 1 -C 6 )alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, a cycloalkyl group, a (C 3 -C 10 )cycloalkyl-(C 1 -C 6 )alkyl group wherein the alkyl moiety is linear or branched, a heterocycloalkyl group, an aryl group or a heteroaryl group, wherein one or more carbon atoms of the preceding groups, or carbon atoms of their possible substituents, may be deuterated;
R 4 represents an aryl group, a heteroaryl group, a cycloalkyl group or a linear or branched (C 1 -C 6 )alkyl group, wherein one or more carbon atoms of the preceding groups, or carbon atoms of their possible substituents, may be deuterated;
R 5 represents a hydrogen or halogen atom, a linear or branched (C 1 -C 6 )alkyl group, or a linear or branched (C 1 -C 6 )alkoxy group;
R 6 represents a hydrogen atom or a linear or branched (C 1 -C 6 )alkyl group;
R a , R b , R c and R d , each independently of the others, represent a hydrogen, a linear or branched (C 1 -C 6 )alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, an aryl group, a heteroaryl group, a halogen atom, a linear or branched (C 1 -C 6 )alkoxy group, a hydroxy group, a linear or branched polyhalo-(C 1 -C 6 )alkyl group, a trifluoromethoxy group, —NR 7 R 7 ′, nitro, R 7 —CO—(C 0 -C 6 )alkyl-, R 7 —CO—NH—(C 0 -C 6 )alkyl-, NR 7 R 7 ′—CO—(C 0 -C 6 )alkyl-, NR 7 R 7 ′—CO-alkyl(C 0 -C 6 )—O—, R 7 —NH—CO—NH—(C 0 -C 6 )alkyl-, R 7 —O—CO—NH—(C 0 -C 6 )alkyl-, a heterocycloalkyl group, or the substituents of one of the pairs (R a ,R b ), (R b ,R c ) or (R c ,R d ) form together with the carbon atoms carrying them a ring composed of from 5 to 7 ring members, optionally having one to 2 hetero atoms selected from the group consisting of oxygen and sulphur, wherein one or more carbon atoms of the ring defined hereinbefore may be deuterated oar substituted by from one to 3 groups selected from the group consisting of halogen and linear or branched (C 1 -C 6 )alkyl,
R 7 and R 7 ′, each independently of the other, represent a hydrogen, a linear or branched (C 1 -C 6 )alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, an aryl group or a heteroaryl group, or R 7 and R 7 ′ form together with the nitrogen atom carrying them a heterocycle composed of from 5 to 7 ring members;

wherein when the compound of formula (I) contains a hydroxyl group, the latter may be optionally substituted by one of the following groups: —PO(OM)(OM′), —PO(OM)(O − M 1 + ), —PO(O − M 1 + )(O − M 2 + ), —PO(O − )(O − )M 3 2+ , —PO(OM)(O[CH 2 CH 2 O] n CH 3 ), or —PO(O − M 1 + )(O[CH 2 CH 2 O] n CH 3 ), wherein M and M′ independently of one another represent a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, a cycloalkyl or a heterocycloalkyl, both composed of from 5 to 6 ring members, while M 1 + and M 2 + independently of one another represent a pharmaceutically acceptable monovalent cation, M 3 2+ represents a pharmaceutically acceptable divalent cation, and n is an integer from 1 to 5;
wherein
“aryl” means a phenyl, naphthyl, biphenyl or indenyl group,
“heteroaryl” means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and from 1 to 4 hetero atoms selected from the group consisting of oxygen, sulphur and nitrogen,
“cycloalkyl” means any mono- or bi-cyclic, non-aromatic, carbocyclic group having from 3 to 10 ring members,
“heterocycloalkyl” means any mono- or bi-cyclic, non-aromatic group composed of from 3 to 10 ring members and having from 1 to 3 hetero atoms selected from the group consisting of oxygen, sulphur, SO, SO 2 and nitrogen;

wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups defined above and the alkyl, alkenyl, alkynyl and alkoxy groups may be optionally substituted by 1 to 3 groups selected from the group consisting of optionally substituted, linear or branched (C 1 -C 6 )alkyl, (C 3 -C 6 )spiro, optionally substituted linear or branched (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkyl-S—, hydroxy, oxo (or N-oxide where appropriate), nitro, cyano, —COOR′, —OCOR′, NR′R″, linear or branched polyhalo-(C 1 -C 6 )alkyl, trifluoromethoxy, (C 1 -C 6 )alkylsulphonyl, halogen, optionally substituted aryl, heteroaryl, aryloxy, arylthio, cycloalkyl, heterocycloalkyl optionally substituted by one or more halogen atoms or alkyl groups, wherein R′ and R″, each independently of the other, represent a hydrogen atom or an optionally substituted, linear or branched (C 1 -C 6 )alkyl group,
its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base, alone or in combination with one or more pharmaceutically acceptable excipients.

2. The method according to claim 1 , wherein R 4 represents a phenyl substituted in the para-position by a group of the formula —OPO(OM)(OM′), —OPO(OM)(O − M 1 + ), —OPO(O − M 1 + )(O − M 2 + ), —OPO(O − )(O − )M 3 2+ , —OPO(OM)(O[CH 2 CH 2 O] n CH 3 ), or —OPO(O − M 1 + )(O[CH 2 CH 2 O] n CH 3 ), wherein M and M′ independently of one another represent a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, a cycloalkyl or a heterocycloalkyl, both composed of from 5 to 6 ring members, while M 1 + and M 2 + independently of one another represent a pharmaceutically acceptable monovalent cation, M 3 2+ represents a pharmaceutically acceptable divalent cation, and n is an integer from 1 to 5, wherein the phenyl group may be optionally substituted by one or more halogen atoms.

3. The method according to claim 1 , wherein W represents a group C—H, and A 1 and A 2 represent a hydrogen atom and a methyl group, respectively.

4. The method according to claim 1 , wherein W represents a group C—H, and A 1 and A 2 , together with the carbon atoms carrying them, form a cyclohexenyl or a benzo ring optionally substituted by a halogen atom.

5. The method according to claim 1 , wherein W represents a nitrogen atom, and A 1 and A 2 , together with the carbon atoms carrying them,

Assignees

• Servier Lab
• Vernalis R&D Ltd

Inventors

• Casara Patrick
• Le Diguarher Thierry
• Henlin Jean-Michel
• Starck Jérôme-Benoît
• Le Tiran Arnaud
• De Nanteuil Guillaume
• Geneste Olivier
• Davidson James Edward Paul
• Murray James Brooke
• Chen I-Jen
• Walmsley Claire
• Graham Christopher John
• Ray Stuart
• Maddox Daniel
• Bedford Simon

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• C07D401/10 Primary

  linked by a carbon chain containing aromatic rings · CPC title